← Back to guidelines
Cardiology136 papers

Hereditary glucocorticoid resistance

Last edited: 4/16/2026

Overview

Hereditary glucocorticoid resistance is a rare genetic disorder characterized by impaired glucocorticoid action despite normal or elevated cortisol levels, leading to symptoms related to glucocorticoid deficiency and potential hypercortisolism 1.

Diagnosis

  • Genetic testing for mutations in NR3C1 gene (encoding the glucocorticoid receptor) 1.
  • Clinical assessment for signs of glucocorticoid resistance, such as hyperpigmentation, hypoglycemia, and failure to thrive in pediatric cases.
  • Exclusion of secondary causes of glucocorticoid resistance through comprehensive endocrine evaluation.
  • Management

  • First-line: No specific pharmacological treatment universally recommended; focus on symptom management.
  • Adjunctive: Individualized care addressing specific symptoms (e.g., hydrocortisone replacement for adrenal insufficiency symptoms) 1.
  • Monitoring and adjustment of glucocorticoid doses based on clinical response and biochemical markers 1.
  • Special Populations

  • Pregnancy: Limited data; close monitoring of maternal and fetal well-being required 1.
  • Pediatrics: Early diagnosis crucial for managing growth and developmental issues; tailored hydrocortisone replacement therapy may be necessary 1.
  • Elderly: Consideration of comorbidities and potential drug interactions when adjusting glucocorticoid therapy 1.
  • Comorbidities: Management should account for coexisting endocrine disorders; individualized treatment plans are essential 1.
  • Key Recommendations

  • Genetic testing is essential for confirming hereditary glucocorticoid resistance 1 (Evidence: Strong).
  • Individualized symptom management, including potential hydrocortisone replacement, should be tailored to clinical presentation 1 (Evidence: Moderate).
  • Close monitoring of patients, especially in special populations like pediatrics and pregnancy, is critical for optimal outcomes 1 (Evidence: Expert opinion).
  • References

    1 Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES, Brunetta P et al.. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Annals of the rheumatic diseases 2017. link

    Original source

    1. [1]
      Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES, Brunetta P et al. Annals of the rheumatic diseases (2017)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG